Research & Development
vasopharm raises EUR9.5m in financing round
11 July 2019 -

Biopharmaceutical company vasopharm GmbH revealed on Wednesday the completion of a EUR9.5m financing agreement co-led by HeidelbergCapital Private Equity and EF Investments.

The financing round included existing investors Bayern Kapital, Future Capital, Hanseatic Asset Management and Ringtons Holdings. Creathor Ventures was a new investor.

Under the terms of the financing, Christian Leikert, partner at Creathor Ventures, joins vasopharm's board of directors.

The new funding will allow vasopharm to complete Chemistry, Manufacturing and Controls (CMC) scale up and stability testing in preparation for commercial scale production, ahead of the potential filing of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for traumatic brain injury (TBI).



Related Headlines